Saturday, February 28th4.7°C
25355
24657

AstraZeneca share price up 15 per cent after Pfizer discloses details of $100 billion offer

LONDON - Shares in Anglo-Swedish drugmaker AstraZeneca jumped 15 per cent on Monday after U.S. pharmaceutical firm Pfizer said it offered to buy the company for around $100 billion.

Pfizer, the maker of Viagra, said that AstraZeneca rejected an initial approach in January valuing the company at about 59 billion pounds ($100 billion). The cash and shares deal would represent a 30 per cent premium on AstraZeneca's closing share price of 35.26 pounds on Jan. 3, around the time the offer was made.

AstraZeneca PLC said it concluded that the proposal "very significantly undervalued AstraZeneca and its prospects."

Another effort to revive discussions took place Saturday, though Pfizer said Astra did not engage. Pfizer remains interested and is confident a combination is possible, issuing a statement to the markets underscoring the potential advantages of the deal.

"Pfizer believes the strategic, business and financial rationale for a transaction is compelling," the company said in a statement.

Shares traded Monday at 46.77 pounds after the approach was revealed.

The deal comes as drugmakers take advantage of lower interest rates in a spate of mergers and acquisitions. One such deal last week involved Swiss drugmaker Novartis AG, which agreed to swap its vaccine business for GlaxoSmithKline PLC's cancer drug unit and sold its veterinary drug arm to Eli Lilly and Co.

Pharmaceutical companies are trying to boost sales and cut costs as many see revenue flat line or even dip due to increased competition from generic drugs and rising expenses for the development of new products.

Pfizer's bid for AstraZeneca would mark the biggest-ever foreign takeover of a British business, and it is possible the Conservative-led government of David Cameron may take a position on the matter, particularly since it has taken an interest in bolstering the country's biotech sectors.

"It would raise fears about the protection of AstraZeneca's innovative research program in the U.K., especially given that Pfizer has already looked at the U.K. and decided to remove its own R&D operations," said Sarah Main, the director of Campaign for Science and Engineering, an independent advocate for science and engineering in the U.K.

AstraZeneca is currently undergoing a major research and development re-organization to offset the expiration on patents for drugs like cholesterol medication, Crestor. The company has been reducing costs and trying to make research programs more productive.

The Canadian Press


Read more Business News

25195


Recent Trending




Today's Market
S&P TSX15234.34-6.82
S&P CDNX706.73+5.80
DJIA18132.70-81.72
Nasdaq4963.528-24.362
S&P 5002104.50-6.24
CDN Dollar0.7996+0.0004
Gold1203.00+6.10
Oil52.14+1.53
Lumber297.20+1.20
Natural Gas2.895-0.007

 
Okanagan Companies
Pacific Safety0.12+0.005
Knighthawk0.010.00
QHR Technologies Inc1.55-0.03
Cantex0.035-0.005
Anavex Life Sciences0.190.00
Metalex Ventures0.035-0.005
Russel Metals25.38+0.08
Copper Mountain Mining1.30+0.04
Colorado Resources0.15+0.015
ReliaBrand Inc0.008-0.0007
Sunrise Resources Ltd0.05+0.015
Mission Ready Services0.235+0.025

 



25048

FEATURED Property
2219397RV with Million Dollar View
more details
image2image2image2
Click here to feature your property
Please wait... loading


Creating your retirement vision

A vision means different things to different people. To the head of a large corporation, it’s the ability to chart a course that will deliver success (think Steve Jobs and Apple), to a shaman, i...


It's OK to say 'I'm sorry'

Photo: ContributedStand-up comedians and sitcoms have been making fun of Canadians for being polite as long as I can remember. Being known for our niceness is certainly not a bad thing and I wish more...


Are you asking the right questions?

Have you ever had this happen to you? You are in the middle of your second or third good discussion with a prospect and everything seems to be going great. The prospect seems engaged and happy to work...

_








Member of BC Press Council


24843